2 A Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Patients with Parkinson’s Disease: Neuropsychological Outcomes

Objective: Parkinson’s disease (PD) is associated with metabolic disorders such as insulin resistance. Pharmacological intervention used to treat insulin resistance, like GLP-1 agonists, may have auspicious results in the treatment for PD. The objective of this clinical trial was to assess the thera...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International Neuropsychological Society 2023-11, Vol.29 (s1), p.109-109
Main Authors: Wertheimer, Jeffrey C, Hogg, Elliot, Wu, Tina, Gottuso, Ann, Gold, Dov, Tagliati, Michele
Format: Article
Language:English
Subjects:
Activities of daily living
Agonists
Anxiety
Avoidance behavior
Clinical trials
Cognitive ability
Dementia disorders
Executive function
Insulin resistance
Metabolic disorders
Motor task performance
Movement and Movement Disorders
Movement disorders
Neurodegenerative diseases
Neuropsychology
Parkinson's disease
Patients
Placebos
Poster Session 01: Medical | Neurological Disorders | Neuropsychiatry | Psychopharmacology
Quality of life
Titration
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Parkinson’s disease (PD) is associated with metabolic disorders such as insulin resistance. Pharmacological intervention used to treat insulin resistance, like GLP-1 agonists, may have auspicious results in the treatment for PD. The objective of this clinical trial was to assess the therapeutic effect of liraglutide on non-motor symptoms, such as, but not limited to, cognitive function and emotional well-being, and quality of life for individuals with PD. Participants and Methods: In a single-center, randomized, double-blind, placebo-controlled trial, PD patients self-administered liraglutide injections once-daily (1.2 or 1.8 mg, as tolerated) or placebo in a 2:1 study design for 52 weeks after titration. Primary outcomes included adjusted difference in the OFF-state Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) part III, non-motor symptom scale (NMSS) and Mattis Dementia Rating Scale (MDRS-2). Secondary outcomes included quality of life scores (Parkinson Disease Questionnaire, PDQ-39) and other neuropsychological tests, including Delis-Kaplan Executive Function System (DKEFS), Geriatric Depression Scale (GDS), and Parkinson’s Anxiety Scale (PAS) scores. Results: Sixty-three subjects were enrolled and randomized to liraglutide (n=42) or placebo (n=21). Mean age in years was 63.5 (9.8) and 64.2 (6.4) for liraglutide and placebo cohorts, respectively (p=0.78), and mean age at symptom onset was 58.9 (10.5) and 59.3 (7.5) for liraglutide and placebo cohorts, respectively (p=0.86). At 54 weeks, NMSS scores had improved by 6.6 points in the liraglutide group and worsened by 6.5 points in the placebo group, a 13.1 point adjusted mean difference (p
ISSN:1355-6177
1469-7661
DOI:10.1017/S135561772300200X